We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Alergia a la vacuna Pfizer-BioNTech® demostrada mediante pruebas cutáneas.
- Authors
Estrada-García, Carlos David; Macías-Robles, Ana Paola; Cortés-Grimaldo, Rosa María; Carvajal-Alonso, Hilda Lilian; Barreto-Alcalá, Marlen; Ramírez-Nepomuceno, Adriana; Esparza-Amaya, David; Coronado-Hernández, Kareli Guadalupe; Barrios-Díaz, Britza; Campos-Téllez, Héctor Hugo
- Abstract
Background: The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered. Case report: 30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered. Conclusion: An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
- Publication
Revista Alergia de Mexico, 2022, Vol 69, Issue 2, p89
- ISSN
0002-5151
- Publication type
Article
- DOI
10.29262/ram.v69i2.1088